162 related articles for article (PubMed ID: 9756756)
1. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
Baltch AL; Smith RP; Ritz WJ; Bopp LH
Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory and bactericidal effects of telithromycin (HMR 3647, RU 56647) and five comparative antibiotics, used singly and in combination, against vancomycin-resistant and vancomycin-susceptible enterococci.
Baltch AL; Smith RP; Ritz WJ; Bopp LH
Chemotherapy; 2001; 47(4):250-60. PubMed ID: 11399861
[TBL] [Abstract][Full Text] [Related]
3. Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin.
Kohner PC; Patel R; Uhl JR; Garin KM; Hopkins MK; Wegener LT; Cockerill FR
J Clin Microbiol; 1997 Dec; 35(12):3258-63. PubMed ID: 9399530
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations.
Hayden MK; Koenig GI; Trenholme GM
Antimicrob Agents Chemother; 1994 Jun; 38(6):1225-9. PubMed ID: 8092818
[TBL] [Abstract][Full Text] [Related]
6. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
7. Simple test of synergy between ampicillin and vancomycin for resistant strains of Enterococcus faecium.
Green M; Barbadora K; Wadowsky RM
J Clin Microbiol; 1994 Nov; 32(11):2837-9. PubMed ID: 7852581
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
Hershberger E; Aeschlimann JR; Moldovan T; Rybak MJ
Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
[TBL] [Abstract][Full Text] [Related]
9. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Houlihan HH; Rybak MJ
Antimicrob Agents Chemother; 1997 Jun; 41(6):1307-12. PubMed ID: 9174189
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
12. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
Zelenitsky SA; Booker B; Laing N; Karlowsky JA; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 1999 Mar; 43(3):592-7. PubMed ID: 10049272
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
Eliopoulos GM; Wennersten CB
Antimicrob Agents Chemother; 2002 May; 46(5):1319-24. PubMed ID: 11959562
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):119-23. PubMed ID: 10677922
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
[TBL] [Abstract][Full Text] [Related]
16. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
Saleh-Mghir A; Lefort A; Petegnief Y; Dautrey S; Vallois JM; Le Guludec D; Carbon C; Fantin B
Antimicrob Agents Chemother; 1999 Jan; 43(1):115-20. PubMed ID: 9869575
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
18. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
Zelenitsky SA; Karlowsky JA; Zhanel GG; Hoban DJ; Nicas T
Antimicrob Agents Chemother; 1997 Jun; 41(6):1407-8. PubMed ID: 9174212
[No Abstract] [Full Text] [Related]
19. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
Al-Nawas B; Swantes J; Shah PM
Infection; 2000; 28(4):214-8. PubMed ID: 10961526
[TBL] [Abstract][Full Text] [Related]
20. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
